Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and Placebo

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2005
Assess the efficacy of a new drug (a receptor agonist that modulates the glutamatergic activity) in the treatment of schizophrenia. The primary objective of this study is to determine if a mGlu2/3 agonist dosed for 28 days is superior to placebo in the treatment of patients with schizophrenia as measured by the Positive and Negative Symptom Scales (PANSS) total score.
Epistemonikos ID: 25ab36834328bc33e37dae18b46df970e5dc2ae2
First added on: May 04, 2024